Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Gastrointestinal (Colorectal) Cancer

Type: Poster Session

Time: Monday June 3, 8:00 AM to 11:00 AM

Location: Hall A

Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder.

Sub-category:
Advanced Disease

Category:
Gastrointestinal (Colorectal) Cancer

Meeting:
2019 ASCO Annual Meeting

Abstract No:
3561

Poster Board Number:
Poster Session (Board #53)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 3561)

Author(s): Reese Garcia, Andrea Dwyer, Sharyn Worrall, Christopher Ryan Heery, Dustin A. Deming, Al Bowen Benson, Anjee Davis; Fight Colorectal Cancer, Springfield, MO; University of Colorado Cancer Center, Aurora, CO; Bavarian Nordic, Inc., Morrisville, NC; University of Wisconsin Carbone Cancer Center, Madison, WI; Northwestern Medicine, Chicago, IL

Abstract Disclosures

Abstract:

Background: Colorectal cancer (CRC) remains one of the most lethal cancer killers worldwide. Recently, research has shown great strides in the treatment of MSI-H mCRC using immunotherapy, however, these treatments have not been effective in MSS patients, who make up a majority of CRC cases. Due to numerous barriers, clinical trial enrollment numbers remain as low as 9% of the eligible populations, despite the reliance of many late stage CRC patients on clinical trials for treatment. Perhaps greatest of these barriers is the lack of meaningful patient-facing clinical trial matching, making advances in MSS mCRC IO clinical research extremely slow. Methods: In May 2017, Fight Colorectal Cancer (FightCRC) launched its web-based trial finder, The Late Stage MSS Trial Finder (TF) with the late Dr. Tom Marsilije, a stage IV CRC patient and researcher, and Flatiron Health. The TF is a publicly available immunotherapy-based repository of clinical trials. An algorithm automatically codes for a subset of trials from ClinicalTrials.gov to be uploaded into the tool, and trained FightCRC advocates follow a strategic logic flow to prioritize trials of highest potential benefit and lowest risk for patients. Results: Between 30 and 100 trials are uploaded into the TF for curation each week. A total of 378 trials have been indexed in the TF to date. In February 2019, a mobile application was introduced. From May 2017 to January 2019, the tool has seen > 15,000 users, yielding 26,000 searches in 105 countries; primarily from the United States, China, the United Kingdom, Canada, and France. On average, users navigate to 2.5 pages and spend > 2.5 minutes per use. Providers are using this as a tool to find clinical trials and to discuss these options in real time. CRC patient feedback confirmed the platform functionality. Conclusions: The Trial Finder is a unique tool for MSS mCRC patients pursuing clinical trials. The success of the tool may be attributed to patient focused selection of therapies that show promise. The FightCRC late stage MSS CRC trial finder is being widely utilized, in diverse settings. With our patient curators and Medical Advisory Board, FightCRC will improve the search features and outcome tracking with user feedback. The goal for the TF is to address key barriers to patient entry into clinical trials and promote patient-provider discussions to inform decision making.

 
Other Abstracts in this Sub-Category:

 

1. Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 3507 First Author: Javier Sastre
Category: Gastrointestinal (Colorectal) Cancer - Advanced Disease

 

2. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3508 First Author: Chiara Cremolini
Category: Gastrointestinal (Colorectal) Cancer - Advanced Disease

 

3. A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3509 First Author: Filippo Pietrantonio
Category: Gastrointestinal (Colorectal) Cancer - Advanced Disease

 

More...